Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TCR2 THERAPEUTICS INC.

(TCRR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). It is conducting Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its lead TRuC-T cell, which targets hematological malignancies is TC-110. It is conducting Phase I/II clinical trial for TC-110 to treat patients with adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin's lymphoma (NHL). Its other product candidates include TC-510, IL-15, CD70 and GPC3, which focuses on solid tumors.

Number of employees : 118 people.
Managers
Name Title Age Since
Garry E. Menzel, Dr. President, Chief Executive Officer & Director 55 2016
Mayur Ian Somaiya Chief Financial Officer 46 2018
Robert Hofmeister, Dr. Chief Scientific Officer 52 -
Alfonso Quintßs-Cardama, Dr. Chief Medical Officer 49 2017
Peter Olagunju Chief Technical Officer - 2021
Ansbert K. Gadicke, Dr. Chairman 62 2015
Neil W. Gibson, Dr. Independent Director 64 2018
Andrew R. Allen, Dr. Independent Director 53 2018
Axel Hoos, Dr. Independent Director 50 2020
Stephen W. Webster Independent Director 59 2020
Members of the board
Name Title Age Since
Ansbert K. Gadicke, Dr. Chairman 62 2015
Garry E. Menzel, Dr. President, Chief Executive Officer & Director 55 2016
Neil W. Gibson, Dr. Independent Director 64 2018
Andrew R. Allen, Dr. Independent Director 53 2018
Axel Hoos, Dr. Independent Director 50 2020
Stephen W. Webster Independent Director 59 2020
Shawn Cline Tomasello Independent Director 61 2021
Priti S. Hegde, Dr. Independent Director - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 38,220,444 36,835,946 96.4% 0 0.0% 96.4%
Shareholders
NameEquities%
MPM Capital Inc 4,050,865 10.6%
Redmile Group LLC 3,816,709 9.99%
Bioimpact Capital LLC 3,370,982 8.83%
MPM Oncology Impact Management LP 3,370,982 8.83%
SSgA Funds Management, Inc. 1,514,717 3.97%
The Vanguard Group, Inc. 1,406,389 3.68%
China Molybdenum Co., Ltd. 1,281,392 3.35%
ArrowMark Colorado Holdings LLC 1,213,498 3.18%
Deerfield Management Company LP 1,200,000 3.14%
Wellington Management Co. LLP 1,131,347 2.96%
Company contact information
TCR2 Therapeutics, Inc.
100 Binney Street
Suite 710
Cambridge, MA 02142

Phone : +1.617.949.5200
Web : http://www.tcr2.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of TCR2 Therapeutics Inc.
Sector Other Biotechnology & Medical Research